We are live on ! Find out more
AARD

Aardvark Therapeutics
AARD

27 hedge funds and large institutions have $65.1M invested in Aardvark Therapeutics in 2025 Q1 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

40.63% more ownership

Funds ownership: 0% → 40.63% (+41%)

Holders
27
Holders Change
+27
Holders Change %
–
% of All Funds
0.36%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
27
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DC
Decheng Capital
California
+$44M
2
Citadel Advisors
Citadel Advisors
Florida
+$14.3M
3
LCM
Laurion Capital Management
New York
+$9.08M
4
CAM
Cormorant Asset Management
Massachusetts
+$8.98M
5
B
Braidwell
Connecticut
+$5.61M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
DC
1
Decheng Capital
California
$29.4M +$44M +3,917,299 New
Citadel Advisors
2
Citadel Advisors
Florida
$9.44M +$14.3M +1,274,084 New
LCM
3
Laurion Capital Management
New York
$6.07M +$9.08M +808,243 New
CAM
4
Cormorant Asset Management
Massachusetts
$6.01M +$8.98M +800,189 New
B
5
Braidwell
Connecticut
$3.75M +$5.61M +500,000 New
SCM
6
Suvretta Capital Management
New York
$2.35M +$3.51M +312,500 New
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$1.88M +$2.81M +250,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.24M +$1.86M +165,491 New
SSA
9
Schonfeld Strategic Advisors
New York
$1.08M +$1.62M +143,951 New
SCM
10
Silverarc Capital Management
Massachusetts
$897K +$1.34M +119,496 New
CF
11
Cantor Fitzgerald
New York
$501K +$749K +66,682 New
Millennium Management
12
Millennium Management
New York
$493K +$737K +65,640 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$448K +$669K +59,600 New
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$266K +$398K +35,435 New
BNP Paribas Financial Markets
15
BNP Paribas Financial Markets
France
$261K +$390K +34,690 New
Goldman Sachs
16
Goldman Sachs
New York
$153K +$228K +20,311 New
BlackRock
17
BlackRock
New York
$141K +$211K +18,776 New
Two Sigma Investments
18
Two Sigma Investments
New York
$116K +$173K +15,424 New
UBS Group
19
UBS Group
Switzerland
$110K +$165K +14,705 New
Squarepoint
20
Squarepoint
New York
$107K +$159K +14,186 New
Northern Trust
21
Northern Trust
Illinois
$105K +$157K +14,001 New
PD
22
Point72 (DIFC)
United Arab Emirates
$96.1K +$144K +12,797 New
Walleye Capital
23
Walleye Capital
New York
$88.1K +$132K +11,730 New
Bank of America
24
Bank of America
North Carolina
$34.7K +$51.9K +4,620 New
JP Morgan Chase
25
JP Morgan Chase
New York
$23.3K +$34.8K +3,100 New
1
2

AARD Hedge Fund Activity: Q1 2025 in Review

27 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q1 2025, worth a combined $65.1M.

Buyers outnumbered sellers: 27 funds opened new AARD positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Decheng Capital, opening a new position worth an estimated $44M.

  • 27 institutional investors held Aardvark Therapeutics (AARD) as of Q1 2025, up from 0 in Q4 2024.
  • Funds reported $65.1M of Aardvark Therapeutics stock for Q1 2025.
  • 27 funds opened new Aardvark Therapeutics positions in Q1 2025 and 0 closed out, a net change of +27 holders.
  • The largest Aardvark Therapeutics buyer in Q1 2025 was Decheng Capital, an estimated $44M added.

Based on aggregated 13F filings for Q1 2025.